Clinical trial
Intravenous Injection of Human Bone Marrow Mesenchymal Stem Cell (hBMMSC) in the Treatment of Autism Spectrum Disorder (ASD): An Exploratory Study on the Safety and Preliminary Efficacy
NCT07177677 is registered in ClinicalTrials.gov with Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Intravenous Injection of Human Bone Marrow Mesenchymal Stem Cell (hBMMSC) in the Treatment of Autism Spectrum Disorder (ASD): An Exploratory Study on the Safety and Preliminary Efficacy
- Lead sponsor
- Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- September 30, 2025
- Completion date
- August 30, 2028
- Enrollment
- 42 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.